LI
ADAP

Leap Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

Leap Investments’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$402K Buy
+40,200
New +$252K 0.26% 136

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Leap Investments's ADAP Position: Q2 2020 in Review

Leap Investments opened a new position in Adaptimmune Therapeutics (ADAP) in Q2 2020: 40,200 shares worth $402K. The stake represents 0.26% of the portfolio and ranks #136 among its holdings.

77 funds tracked by Wall St. Rank hold ADAP as of Q2 2020.

  • Leap Investments held 40,200 shares of Adaptimmune Therapeutics worth $402K as of Q2 2020.
  • Adaptimmune Therapeutics was a new Leap Investments position in Q2 2020.
  • Adaptimmune Therapeutics made up 0.26% of Leap Investments's portfolio in Q2 2020, its #136 holding.
  • 77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.